CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR–refractory large B-cell lymphoma

The prognosis of patients with large B-cell lymphoma (LBCL) that progresses after treatment with chimeric antigen receptor (CAR) T-cell therapy targeting CD19 (CAR19) is poor. We report on the first 3 consecutive patients with autologous CAR19-refractory LBCL who were treated with a single infusion...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Blood
Main Authors: Baird, John H., Frank, Matthew J., Craig, Juliana, Patel, Shabnum, Spiegel, Jay Y., Sahaf, Bita, Oak, Jean S., Younes, Sheren F., Ozawa, Michael G., Yang, Eric, Natkunam, Yasodha, Tamaresis, John, Ehlinger, Zachary, Reynolds, Warren D., Arai, Sally, Johnston, Laura, Lowsky, Robert, Meyer, Everett, Negrin, Robert S., Rezvani, Andrew R., Shiraz, Parveen, Sidana, Surbhi, Weng, Wen-Kai, Davis, Kara L., Ramakrishna, Sneha, Schultz, Liora, Mullins, Chelsea, Jacob, Allison, Kirsch, Ilan, Feldman, Steven A., Mackall, Crystal L., Miklos, David B., Muffly, Lori
Format: Artigo
Jezik:Inglês
Izdano: American Society of Hematology 2021
Teme:
Clinical Trials and Observations
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC8085484/
https://ncbi.nlm.nih.gov/pubmed/33512414
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2020009432
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki